Structure Therapeutics up after weight-loss drug succeeds mid-stage trial

Shares of Structure Therapeutics GPCR.O rise 15.7% to $41.3 premarket

GPCR's experimental drug aleniglipron at a dosage of 120mg showed an 11.3% reduction in weight in a mid-stage study, a figure that was statistically significant compared to placebo at 36 weeks

The company plans to initiate a late-stage trial in mid-2026

Another study exploring higher doses of aleniglipron showed weight loss of up to 15.3% at 36 weeks

The current landscape for obesity treatments includes Danish drugmaker Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound, both of which dominate the market

Viking Therapeutics' experimental weight-loss pill VK2735 previously failed to surpass Wall Street expectations in August

As of last close, GPCR stock was up 27.4% YTD